Peter Jüni
University of Toronto
H-index: 158
North America-Canada
Description
Peter Jüni, With an exceptional h-index of 158 and a recent h-index of 114 (since 2020), a distinguished researcher at University of Toronto, specializes in the field of Clinical Epidemiology, Epidemiology, Cardiology, Clinical Trials, Meta-Analysis.
His recent articles reflect a diverse array of research interests and contributions to the field:
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of …
Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis: a network meta-analysis of large randomized trials
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of …
Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre …
Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through …
Professor Information
University | University of Toronto |
---|---|
Position | Director AHRC St. Michael's Hospital and Professor of Medicine |
Citations(all) | 250578 |
Citations(since 2020) | 175800 |
Cited By | 129153 |
hIndex(all) | 158 |
hIndex(since 2020) | 114 |
i10Index(all) | 515 |
i10Index(since 2020) | 438 |
University Profile Page | University of Toronto |
Research & Interests List
Clinical Epidemiology
Epidemiology
Cardiology
Clinical Trials
Meta-Analysis
Top articles of Peter Jüni
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Aims To conduct a meta‐analysis of randomized controlled trials (RCTs) to assess the effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on inflammatory biomarkers. Methods Medline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity. Results Thirty‐eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow‐up of 16 (12–24) weeks. Meta‐analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin‐6, tumour necrosis factor receptor‐1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model …
Authors
Leonardo Buttice,Maryam Ghani,Janahan Suthakar,Sathyan Gnanalingham,Elliott Carande,Brett WC Kennedy,Alex Pitcher,James HP Gamble,Mahmood Ahmad,Andrew Lewis,Peter Jüni,Oliver J Rider,Jeffrey W Stephens,Jonathan JH Bray
Journal
Diabetes, Obesity and Metabolism
Published Date
2024/4/11
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of …
Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published. Shortly before, a European expert consensus task force produced guidance for clinicians on the management of antithrombotic therapy in patients with ACS as well as chronic coronary syndrome. The scope of this manuscript is to provide a critical appraisal of differences and similarities between the European consensus paper and the latest …
Authors
Antonio Landi,Victor Aboyans,Dominick J Angiolillo,Dan Atar,Davide Capodanno,Keith AA Fox,Sigrun Halvorsen,Stefan James,Peter Jüni,Sergio Leonardi,Roxana Mehran,Gilles Montalescot,Eliano Pio Navarese,Josef Niebauer,Angelo Oliva,Raffaele Piccolo,Susanna Price,Robert F Storey,Heinz Völler,Pascal Vranckx,Stephan Windecker,Marco Valgimigli
Journal
European Heart Journal: Acute Cardiovascular Care
Published Date
2024/1
Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis: a network meta-analysis of large randomized trials
Purpose (the aim of the study): To identify the most effective and safest intra-articular interventions to reduce pain and improve physical function in patients with knee or hip OA.Methods: Data Sources: Electronic searches in the Cochrane Controlled Clinical Trial Register, regulatory agency websites, and ClinicalTrials. gov were performed (database inception to October, 2023).Study Selection: Randomized trials reported in English with≥ 100 patients per group that compared any intra-articular intervention to another intra-articular treatment, placebo or standard care.Main Outcomes and Measures: The prespecified primary outcome was pain intensity. We also assessed physical function and safety outcomes. Both pain intensity and physical function were evaluated at multiple time points: 2, 6, 12, 24 and 52 weeks after randomization.Data Extraction and Synthesis: Data were independently extracted by two …
Authors
Tiago V Pereira,Pakeezah Sadaat,Pavlos Bobos,Samir Iskander,Nicolas S Bodmer,Martina Rudnicki,Henry D Kiyomoto,Thais Montezuma,Matheus O Almeida,Rishi Bansal,Pai-Shan Cheng,Alex J Sutton,Peter Tugwell,Gillian Hawker,Peter Jüni,Bruno R da Costa
Journal
Osteoarthritis and Cartilage
Published Date
2024/4/1
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
ImportanceAbbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).ObjectivesTo evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR.Design, Setting, and PatientsThis prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients with HBR were randomized at 1 month after PCI to abbreviated or standard DAPT. Data were analyzed from July 1 to October 31 …
Authors
Antonio Landi,Mirvat Alasnag,Dik Heg,Enrico Frigoli,Fazila Tun Nesa Malik,Ivan Gomez-Blazquez,Suzanne Pourbaix,Alaide Chieffo,Christian Spaulding,Fermin Sainz,Helen Routledge,Giuseppe Andò,Luca Testa,Alessandro Sciahbasi,Hussain Contractor,Nigel Jepson,Juan Mieres,Syed Saqib Imran,Husam Noor,Pieter C Smits,Marco Valgimigli,Peter C Smits,GA Van Es,GBWE Vos,E Spitzer,Pascal Vrancks,Bernard Chevalier,Yukio Ozaki,Marie-Claude Morice,Stephan Windecker,Yoshinobu Onuma,Andrè Frenk,Peter C Jüni,Jan Tijssen,D Paunovic,Mullasari S Ajit,Jozef Bartunek,Antonio Colombo,David Hildick-Smith,Andrés Iñiguez,Felix Mahfoud,Ran Kornowski,Maciej Lesiak,Paul JL Ong,Alfredo E Rodriguez,Marco Roffi,Carl Schultz,Goran Stankovic,Pim Tonino,Aris Moschovitis,Peep Laanmets,Michael Donahue,M Bertrand,Stuart Pocock,Philip Urban,Sergio Leonardi,Claude Hanet,Renato Lopes,Eùgene P McFadden,Peter Radke,Risto O Roine,Boudijn Ladan,Laura van der Waal,Yvonne Engelbrecht,Fred Paddenburg,Ben Ren,Ingrid de Zwart,Liliane Elshout,Judith Jonk,Tessa Rademaker-Havinga,Ria van Vliet,Phani Krishna Kondamudi,Laure Morsiani,Ute Windhövel,Anita van der Wal,Chantal Bakker,Kazuhiro Minagawa,Fernando Cura,Carlos Fernandez-Pereira,Astin Lee,Robert Whitbourn,Owen Christopher Raffel,Kurt Huber,Franz Weidinger,Jessa Ziekenhuis,Imelda Ziekenhuis,Willem Dewilde,Adel Aminian,Emanuele Aalst,Panagiotis Xaplanteris,Vasil Velchev,Dimitar Karageorgiev,Hristo Mateev,Valeri Gelev,Petr Kala,Martin Mates,Henning Kelbæk,Thomas Hovasse,Laurent Delorme,Thomas Cuisset,Loïc Belle,Farzin Beygui,Christophe Piot,Jean François Morelle,Rene Koning,Mathieu Valla,Philippe Brunel,Guillaume Cayla,Emmanuel Teiger,Gilles Montalescot,Phillipe Guyon,Pyxaras Stylianos,Bela Merkely,Imre Ungi,Rajpal K Abhaichand,Atul Damodar Abhyankar,Gunasekaran Sengottuvelu,Halabi Majdi,Ariel Roguin,Yair Feld,Chaim Lotan,Stefano Garducci,Bernhard Reimers,Gennaro Sardella,Antonio Milan,Corrado Tamburino,Maurizio Di Biasi,Paolo Calabro,Gianluigi Minervini,Bruno Loi,Franco Fabbiocchi,Jacopo Oreglia,Paolo Sganzerla,Kenji Ando,Yoshiharu Higuchi,Mamoru Nanasato,Yuki Ishibashi,Hitoshi Matsuo,Ruka Yoshida,Kiyokazu Shimizu,Haruo Kamiya,Nobuyuki Komiyama,Tetsuya Amano,Toyoaki Murohara,Seiji Yamazaki,Sasko Kedev,Jakub Podolec,Krzysztof Reszuch,Adrian Wlodarczak,Dariusz Dudek
Journal
JAMA cardiology
Published Date
2024/1/1
Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial
Background The use of assays detecting cytomegalovirus (CMV)–specific T cell–mediated immunity may individualize the duration of antiviral prophylaxis after transplantation. Methods In this randomized trial, kidney and liver transplant recipients from 6 centers in Switzerland were enrolled if they were CMV-seronegative with seropositive donors or CMV-seropositive receiving antithymocyte globulins. Patients were randomized to a duration of antiviral prophylaxis based on immune monitoring (intervention) or a fixed duration (control). Patients in the control group were planned to receive 180 days (CMV-seronegative) or 90 days (CMV-seropositive) of valganciclovir. Patients were assessed monthly with a CMV ELISpot assay (T-Track CMV); prophylaxis in the intervention group was stopped if the assay was positive. The co-primary outcomes were the proportion of patients with …
Authors
Oriol Manuel,Mirjam Laager,Cédric Hirzel,Dionysios Neofytos,Laura N Walti,Gideon Hoenger,Isabelle Binet,Aurelia Schnyder,Susanne Stampf,Michael Koller,Matteo Mombelli,Min Jeong Kim,Matthias Hoffmann,Katrin Koenig,Christoph Hess,Anne-Valérie Burgener,Pietro E Cippà,Kerstin Hübel,Thomas F Mueller,Daniel Sidler,Suzan Dahdal,Franziska Suter-Riniker,Jean Villard,Andrea Zbinden,Giuseppe Pantaleo,Nasser Semmo,Karine Hadaya,Natalia Enríquez,Pascal R Meylan,Marc Froissart,Dela Golshayan,Thomas Fehr,Uyen Huynh-Do,Manuel Pascual,Christian Van Delden,Hans H Hirsch,Peter Jüni,Nicolas J Mueller
Journal
Clinical Infectious Diseases
Published Date
2024/2/15
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of …
The major aspects of the management of patients with acute coronary syndromes described in this European Society of Cardiology (ESC) Guideline are summarized in Figure 1.
Authors
Robert A Byrne,Xavier Rossello,JJ Coughlan,Emanuele Barbato,Colin Berry,Alaide Chieffo,Marc J Claeys,Gheorghe-Andrei Dan,Marc R Dweck,Mary Galbraith,Martine Gilard,Lynne Hinterbuchner,Ewa A Jankowska,Peter Jüni,Takeshi Kimura,Vijay Kunadian,Margret Leosdottir,Roberto Lorusso,Roberto FE Pedretti,Angelos G Rigopoulos,Maria Rubini Gimenez,Holger Thiele,Pascal Vranckx,Sven Wassmann,Nanette Kass Wenger,Borja Ibanez
Published Date
2024/1
Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre …
RationaleDecompressive craniectomy (DC) is beneficial in people with malignant middle cerebral artery infarction. Whether DC improves outcome in spontaneous intracerebral haemorrhage (ICH) is unknown.AimTo determine whether DC without haematoma evacuation plus best medical treatment (BMT) in people with ICH decreases the risk of death or dependence at 6 months compared to BMT alone.Methods and designSWITCH is an international, multicentre, randomised (1:1), two-arm, open-label, assessor-blinded trial. Key inclusion criteria are age ⩽75 years, stroke due to basal ganglia or thalamic ICH that may extend into cerebral lobes, ventricles or subarachnoid space, Glasgow coma scale of 8–13, NIHSS score of 10–30 and ICH volume of 30–100 mL. Randomisation must be performed <66 h after onset and DC <6 h after randomisation. Both groups will receive BMT. Participants randomised to the …
Authors
Urs Fischer,Christian Fung,Seraina Beyeler,Lukas Bütikofer,Werner Z’Graggen,Florian Ringel,Jan Gralla,Karl Schaller,Nikolaus Plesnila,Daniel Strbian,Marcel Arnold,Werner Hacke,Peter Jüni,Alexander David Mendelow,Christian Stapf,Rustam Al-Shahi Salman,Jenny Bressan,Stefanie Lerch,Claudio LA Bassetti,Heinrich P Mattle,Andreas Raabe,Jürgen Beck
Journal
European stroke journal
Published Date
2024/2/12
Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through …
In an era focused on value-based healthcare, the quality of healthcare and resource allocation should be underpinned by empirical evidence. Pragmatic clinical trials (pRCTs) are essential in this endeavor, providing randomized controlled trial (RCT) insights that encapsulate real-world effects of interventions. The rising popularity of pRCTs can be attributed to their ability to mirror real-world practices, accommodate larger sample sizes, and provide cost advantages over traditional RCTs. By harmonizing efficacy with effectiveness, pRCTs assist decision-makers in prioritizing interventions that have a substantial public health impact and align with the tenets of value-based health care. An international network for pRCT provides several advantages, including larger and diverse patient populations, access to a broader range of healthcare settings, sharing knowledge and expertise, and overcoming ethical and …
Authors
Elmir Omerovic,Mark Petrie,Björn Redfors,Stephen Fremes,Gavin Murphy,Guillaume Marquis-Gravel,Alexandra Lansky,Eric Velazquez,Divaka Perera,Christopher Reid,Julian Smith,Peter van der Meer,Eric Lipsic,Peter Juni,John McMurray,Johann Bauersachs,Lars Køber,Jean L Rouleau,Torsten Doenst
Journal
Trials
Published Date
2024/1/23
Professor FAQs
What is Peter Jüni's h-index at University of Toronto?
The h-index of Peter Jüni has been 114 since 2020 and 158 in total.
What are Peter Jüni's top articles?
The articles with the titles of
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of …
Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis: a network meta-analysis of large randomized trials
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of …
Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre …
Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through …
...
are the top articles of Peter Jüni at University of Toronto.
What are Peter Jüni's research interests?
The research interests of Peter Jüni are: Clinical Epidemiology, Epidemiology, Cardiology, Clinical Trials, Meta-Analysis
What is Peter Jüni's total number of citations?
Peter Jüni has 250,578 citations in total.
What are the co-authors of Peter Jüni?
The co-authors of Peter Jüni are Douglas G Altman, Matthias Egger, Prof Julian Higgins, David Moher, Jonathan Sterne.